MOA Life Plus Co. Ltd. (KOSDAQ:142760)

South Korea flag South Korea · Delayed Price · Currency is KRW
700.00
+10.00 (1.45%)
At close: May 21, 2026
Market Cap29.52B -41.2%
Revenue (ttm)11.22B -28.2%
Net Income-13.05B
EPS-339.65
Shares Out42.17M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume136,838
Average Volume230,607
Open690.00
Previous Close690.00
Day's Range690.00 - 744.00
52-Week Range577.00 - 2,250.00
Betan/a
RSI35.77
Earnings DateMay 22, 2026

About MOA Life Plus

MOA Life Plus Co. Ltd. engages in the medicine and consumer business in South Korea. It offers P53, a target anti-cancer drug. The company’s pipeline products include BLS-H01, which is in phase 3 clinical trial for the treatment of cervical cancer; BLC-H03, a vaccine adjuvant that is in preclinical stage; BLS-M07 that has completed phase 2b clinical trial for the treatment of cervical cancer; and BLS-M22 that has completed phase 1 clinical trial for the treatment of Duchenne muscular dystrophy. It also provides health functional food and raw ma... [Read more]

Founded 1999
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 142760
Full Company Profile

Financial Performance

In 2025, MOA Life Plus's revenue was 11.22 billion, a decrease of -28.24% compared to the previous year's 15.63 billion. Losses were -13.05 billion, 88.6% more than in 2024.

Financial Statements